Diamyd Medical AB (publ)
DYMDF
$0.73
$0.000.00%
OTC PK
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 212.00% | -22.58% | -73.91% | -65.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 212.00% | -22.58% | -73.91% | -65.49% |
| Cost of Revenue | 9.26% | 28.29% | -1.43% | -17.30% | 14.47% |
| Gross Profit | -15.51% | -22.10% | 0.79% | 12.88% | -32.59% |
| SG&A Expenses | 38.28% | 13.32% | 31.44% | 8.95% | 3.64% |
| Depreciation & Amortization | 23.77% | 9.24% | 21.12% | 431.84% | 18.73% |
| Other Operating Expenses | -353.56% | 11.35% | 42.92% | -121.60% | 95.41% |
| Total Operating Expenses | 26.73% | 50.07% | 43.85% | 41.33% | 79.86% |
| Operating Income | -26.90% | -49.92% | -43.93% | -41.56% | -80.83% |
| Income Before Tax | -18.55% | -44.59% | -14.50% | -35.02% | -90.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.55% | -44.59% | -14.50% | -35.02% | -90.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.55% | -44.59% | -14.50% | -35.02% | -90.11% |
| EBIT | -26.90% | -49.92% | -43.93% | -41.56% | -80.83% |
| EBITDA | -27.01% | -51.55% | -44.93% | -42.58% | -84.37% |
| EPS Basic | -8.23% | -31.88% | 2.04% | -11.50% | -51.36% |
| Normalized Basic EPS | -7.41% | -32.26% | -17.76% | 9.02% | -50.93% |
| EPS Diluted | -8.23% | -31.88% | 2.04% | -11.50% | -51.36% |
| Normalized Diluted EPS | -7.41% | -32.26% | -17.76% | 9.02% | -50.93% |
| Average Basic Shares Outstanding | 9.62% | 9.63% | 16.94% | 21.14% | 25.59% |
| Average Diluted Shares Outstanding | 9.62% | 9.63% | 16.94% | 21.14% | 25.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |